These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31601999)

  • 21. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
    Ibrahim AE; Feldman J; Karim A; Kharasch ED
    Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients.
    Solassol I; Caumette L; Bressolle F; Garcia F; Thézenas S; Astre C; Culine S; Coulouma R; Pinguet F
    Oncol Rep; 2005 Oct; 14(4):1029-36. PubMed ID: 16142368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma Concentrations of Fentanyl Achieved With Transdermal Application in Chickens.
    Delaski KM; Gehring R; Heffron BT; Negrusz A; Gamble KC
    J Avian Med Surg; 2017 Mar; 31(1):6-15. PubMed ID: 28358614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed Norfentanyl Clearance During Pregnancy.
    Wanar A; Saia K; Field TA
    Obstet Gynecol; 2020 Nov; 136(5):905-907. PubMed ID: 33030873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.
    Saari TI; Laine K; Neuvonen M; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2008 Jan; 64(1):25-30. PubMed ID: 17987285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.
    Solassol I; Bressolle F; Caumette L; Garcia F; Poujol S; Culine S; Pinguet F
    Ther Drug Monit; 2005 Aug; 27(4):491-8. PubMed ID: 16044107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation.
    Cambic CR; Avram MJ; Gupta DK; Wong CA
    Int J Obstet Anesth; 2014 Feb; 23(1):45-51. PubMed ID: 24333052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
    Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system.
    Takashina Y; Naito T; Mino Y; Yagi T; Ohnishi K; Kawakami J
    Drug Metab Pharmacokinet; 2012; 27(4):414-21. PubMed ID: 22277678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
    Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
    Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
    Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
    Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
    Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
    Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability of transdermal fentanyl metabolism and excretion in pain patients.
    Cole JM; Best BM; Pesce AJ
    J Opioid Manag; 2010; 6(1):29-39. PubMed ID: 20297612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of non-intravenous formulations of fentanyl.
    Lötsch J; Walter C; Parnham MJ; Oertel BG; Geisslinger G
    Clin Pharmacokinet; 2013 Jan; 52(1):23-36. PubMed ID: 23100195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Adile C; Ficorella C
    Curr Med Res Opin; 2010 Dec; 26(12):2765-8. PubMed ID: 21034376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain.
    Ishida T; Naito T; Sato H; Kawakami J
    Drug Metab Pharmacokinet; 2016 Jun; 31(3):242-8. PubMed ID: 27236640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.